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Serum Irisin Levels in Patients with Acute Atrial Fibrillation

ABSTRACT
Objective. e purpose of this research was to investigate whether changes in serum irisin levels can represent a marker of altered energy requirements in patients with acute atrial brillation (AF) undergoing cardioversion (CV).
Methods.
e research was planned as a randomized, prospective case-control study. Patients presenting to the emergency medicine and cardiology departments of a university hospital due to acute AF were included in the study. Irisin levels were measured from serum specimens collected 24 and 72 hours (h) following restoration of sinus rhythm with CV in patients in AF rhythm. e values obtained were then compared using statistical analysis.
Results.
irty-one patients undergoing CV due to acute AF were enrolled. Mean irisin levels were studied from serum specimens collected 24 and 72 h following restoration of sinus rhythm with CV, and were then compared. No statistically signi cant di erence was determined at comparison of patients' basal to 24 h, basal to 72 h, and 24 to 72 h mean irisin values (p=0.734, p=0.958, and p=0.643, respectively). Negative correlation was determined between basal serum irisin levels and LDL (r=-0.519, p=0.002), but no signi cant correlation was observed with epicardial adipose tissue (EAT) thickness. Conclusion. We determined no change in serum irisin levels studied 24 h and 72 h following return of normal sinus rhythm a er CV from basal serum irisin levels in patients with acute AF. No correlation also was determined between serum irisin levels and EAT thickness.
INTRODUCTION
Atrial brillation (AF) is the most common form of cardiac arrhythmia both worldwide and in Turkey and is seen in 1-2% of the global population (1). Whether or not the body's energy requirement has increased, is important in terms of treatment planning in patients with AF and of explaining the body's response to this form of arrhythmia. Some studies of energy metabolism in patients with AF have reported that the AF rhythm increases energy demand (2-5), while others have reported impaired energy production or consumption (6) (7) (8) (9) . ese inconsistent reports from the literature permit no de nite conclusion regarding whether or not energy demand increases in the AF rhythm.
Irisin functions as an adenosine triphosphate (ATP) sensor in local tissues. If there is no energy requirement in the tissue, energy present in physiological irisin lev-els is converted into heat, while if the tissue requires ATP, then irisin production decreases. A low irisin level is thought to bestow some degree of protection against necrosis by inhibiting conversion of ATP into heat (10) (11) (12) .
In order to investigate the relation between AF and energy metabolism, we planned to determine whether basal serum irisin levels in patients with AF would change 24 and 72 hours (h) a er cardioversion (CV).
MATERIALS AND METHODS
Study Population
is single-center, prospective study was performed in the emergency medicine and cardiology departments of a Turkish university hospital. Following receipt of ethical committee approval (No. 2016/32), the study was conducted over an eight-month period between April and December, 2016. Patients undergoing medical or electrical CV procedures due to AF and in whom sinus rhythm was restored were included in the study. Patients with moderate or more severe heart valve disease, heart valve prosthesis, congenital heart disease, hypertrophic cardiomyopathy, permanent pacemaker, an ejection fraction lower than 50%, or with uncontrolled or untreated thyroid function disorder, pregnant pa-tients and patients with kidney failure (creatinine >1.2 mg/dl), chronic liver disease, or diabetes, or aged under 18, were excluded. One hundred forty-nine patients undergoing CV due to AF were evaluated. One hundred eighteen of these patients were excluded for various reasons.
e study was thus nally conducted with 31 patients. e patient selection scheme is shown in Figure 1 . Selection of medical or electrical CV was based on European Society of Cardiology (ESC) 2016 guideline recommendations (1) . All the patients included in the study were hemodynamically stable, and medical or elective electrical CV was performed. No emergency electrical CV was performed in any case. All patients' demographic characteristics, echocardiography (ECHO) ndings, body mass index (BMI) values and CHA2DS2-VASc scores at time of presentation were recorded onto study forms. Routine biochemical parameters including glucose, creatinine, C-reactive protein (CRP), white blood cell count and platelet count obtained by measuring hemoglobin, thyroid stimulating hormone (TSH), free thyroxine (fT4), low-density lipoprotein (LDL), high-density lipoprotein (HDL), and total cholesterol and triglyceride levels were also recorded.
Echocardiographic Evaluation
Transthoracic ECHO was performed at time of presentation on all patients with AF. Patients' echocardiographic measurements were obtained using a Vivid 7 (GE Vingmed Ultrasound, Horten, Norway) ECHO device. Le atrium (LA) diameter, le ventricular end-systolic diameter (LVESD) and end-diastolic diameter (LVEDD), and interventricular septum (IVS) and posterior wall (PW) thicknesses from parasternal long axis images together with epicardial adipose tissue (EAT) thickness were measured. Ejection fraction was calculated from apical four chamber view using the modi ed Simpson method. Right ventricle (RV) and right atrium (RA) diameters were measured. Pulmonary artery pressure (PAP) was measured with continuous Doppler ow from the tricuspid valve jet.
Serum Irisin Measurement
Two milliliters of serum was separated from blood collected from patients diagnosed with acute AF and placed into biochemistry tubes at time of presenta-tion and during routine tests a er 24 h and 72 h. e serum specimens collected were stored at -80 ºC until the study was completed. Irisin levels were determined using an Enzyme-Linked Immunosorbent Assay (ELISA) kit (Elabscience, Cat No. RAG018R, Lot: X17-001, Czech Republic) in line with the manufacturing company's instructions. Serum specimens in storage at -80 °C were brought to room temperature. Irisin standards were prepared in line with the kit procedures. Specimen absorbances were read at a 450 nm wavelength on a VERSA (Designed by Molecular Devices in California, USA) microplate reader. e results were expressed as μg/mL. Other biochemical parameters (glucose, creatinine, cholesterol, etc.) were measured using standard laboratory methods.
Statistical Analysis
Data analysis was performed on SPSS 23.0 statistical so ware. Descriptive statistics were expressed as number and percentage for categorical variables and as mean plus standard deviation for numerical variables. Normal distribution of numerical variables was assessed using the Kolmogorov-Smirnov test. e paired t test was used to compare normally distributed dependent variables. At correlation analysis, Pearson's correlation test was used for normally distributed data, and Spearman's correlation test for non-normally distributed data. Statistical signi cance was set at p<0.05. Table 3 . Signi cant negative correlation was determined only between basal serum irisin levels and the lipid parameter LDL (r= -0.519, p= 0.002). No signi cant correlation was determined between basal serum irisin levels and other lipid parameters, BMI, ECHO ndings, CHA2DS2-VASc score or EAT thickness. e e ects on serum irisin levels of heart failure, hypertension, stroke and basic demographic characteristics, such as sex, were assessed separately, and no signi cant e ect of these parameters on serum irisin levels was observed.
RESULTS
Patients
DISCUSSION
No statistically signi cant di erence was determined in our study between serum irisin levels during acute AF rhythm and at 24 h and 72 h a er restoration of sinus rhythm via CV. Signi cant negative cor- relation was determined only between patients' basal serum irisin levels and the lipid parameter LDL. No signi cant correlation was determined between basal serum irisin levels and other lipid parameters, BMI, ECHO ndings, CHADVASC2 score or EAT thickness. Ours is the rst study to investigate the relation between AF and irisin.
Irisin is released by heart and skeletal muscle, the liver and kidney, the peripheral nerve sheath, and the dermis and hypodermis (12) . Heart muscle cells produce more irisin than skeletal muscles (13) . Irisin has been identi ed as a thermogenic protein responsible for energy consumption by converting white adipose tissue into brown adipose tissue. It activates the thermogenic function by increasing uncoupling protein-1 (UCP-1) expression in subcutaneous adipose tissue. Increased UCP1 results in heat production by reducing ATP synthesis, leading to greater consumption of energy resources (10, 11) . EAT, a brown adipose tissue found between the epicardium and visceral layers of the pericardium, possesses high levels of UCP-1 and protects the myocardium against hypothermia by releasing fatty acid. Studies have shown that EAT thickness is correlated with the severity and incidence of AF (14, 15) . Inammatory cytokines released from EAT are thought to contribute to the persistence of AF (10, 12, 16) . In addition, studies of the relation between irisin levels and myocardial infarction have determined that low irisin levels play a role in protecting myocardial cells against energy loss (12, 17) .
In their experimental study, Kuloglu et al. determined low irisin levels in the rst 24 h of myocardial infarction (12). Aydin et al. observed a gradual decrease up to 48 h in saliva and serum irisin levels in acute myocardial infarction patients, and reported that levels began rising a er 72 h (17) . While it is possible that serum irisin levels decrease gradually for the rst 48 h following CV and establishment of sinus rhythm in AF, and that they subsequently begin increasing, through the same mechanism, a er 72 h, our ndings do not support this hypothesis. We determined no signi cant change in irisin levels at 24 h and 72 h post-CV.
Sahin et al. determined signi cantly higher serum irisin levels and EAT thickness in hyperthyroid patients compared to a control group, and that EAT was positively and independently correlated with serum irisin. ose authors reported that metabolic (22) . Based on these ndings, it is impossible to draw any de nite conclusion concerning the relation between serum irisin and BMI and lipid parameters.
LIMITATIONS
e main limitation to our study is the relatively low number of patients enrolled.
e second limitation is that the data could not be compared against a healthy control group. Additionally, serum irisin values were not investigated 48 h a er CV.
CONCLUSION
We determined no change in acute AF patients' basal irisin levels and those at 24 h and 72 h following restoration of normal sinus rhythm a er CV procedures. In addition, our ndings revealed no correlation between AF patients' EAT thickness and serum irisin levels. More extensive studies are now needed for a better understanding of the association between serum irisin levels and AF and EAT. density lipoprotein cholesterol, LDL-c:Low-density lipoprotein cholesterol, TC:Total cholesterol, TG:Triglycerides, TSH: yroid-stimulating hormone, WBC:White blood cell 
